ArticleCurrent medicinal chemistry2026
Transcriptome-wide Association Studies Integrating Four Levels Identify Novel Targets for Idiopathic Pulmonary Fibrosis.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionIdiopathic pulmonary fibrosis (IPF) is a kind of interstitial lung disease with a poor prognosis. Even though genome-wide association studies (GWAS) have identified numerous loci linked to IPF risk, the underlying causal genes and biological processes are still mostly unknown.
methodsThe IPF GWAS summary data included 4,125 cases, 20,464 controls from five cohorts. The weight file and related files for transcriptome association studies (TWAS) of plasma protein, multi-tissues, cross-tissue, and single-cell were obtained from Zhang's study, Mancuso lab, GTExV8 database, and Thompson's study, respectively. We conducted TWAS employing functional Summary-based Imputation (FUSION) from four levels, which were plasma protein, multiple tissues, cross-tissue, and single cell. Conditional and joint (COJO) analysis and multi-marker analysis of genomic annotation (MAGMA) analysis were used to validate the above results. Summary-data-based Mendelian randomization (SMR) and Bayesian co-localization analysis were utilized to explain the causal association between selected genes and the risk of IPF.
resultsA total of 12, 361, 1187, and 72 genes were calculated from the four dimensions of TWAS. TOLLIP, GCHFR, ZNF318 TALDO1, CD151, and AP4M1 were selected by intersecting the results of the four sets of genes. GCHFR, TALDO1, CD151, and AP4M1 were verified by COJO analysis and MAGMA analysis. SMR and colocalization analyses identified GCHFR as the most significant gene for IPF. DISCUSSION: We have applied the TWAS approach to identify novel therapeutic targets for IPF in multiple dimensions. Further biological testing will be required in future studies to validate our findings.
conclusionIn summary, we carried out an extensive TWAS that integrated four dimensions: plasma protein, multiple tissues, cross-tissue, and single cell. GCHFR was identified as the most significant gene for IPF in this study.
Indexed as
Identifiers
40873285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.